Indicators
Indicators
Value
Direction
MACD(12,26,9)
-2.594
Neutral
RSI(14)
47.278
Neutral
STOCH(KDJ)(9,3,3)
12.578
Oversold
ATR(14)
5.007
Low Volatility
CCI(14)
-157.150
Sell
Williams %R
93.898
Oversold
TRIX(12,20)
0.324
Sell
StochRSI(14)
0.000
Sell
Repligen Corp
RGEN160.550USD
+3.160+2.01%
Market hours （ET）Quotes delayed by 15 min
9.04BMarket Cap
5754.48P/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Repligen Corp
Currency: USD Updated: 2025-12-12Key Insights
Repligen Corp's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 19/208 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 187.96.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Repligen Corp's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
22
analysts
Buy
Current Rating
187.959
Target Price
+16.88%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Repligen Corp Highlights
StrengthsRisks
Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems. Its focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Its filtration products are used in process development and process scale (clinical and commercial) production. Its XCell ATF systems are used in upstream perfusion (continuous) and N-1 (intensified fed-batch or hybrid perfusion) cell culture processing. Its chromatography franchise includes several products used in downstream purification, development, manufacturing and quality control of biological drugs. Its process analytics products complement and support its filtration, chromatography and protein franchises. Its TangenX product portfolio includes flat sheet (FS) tangential flow filtration (TFF) cassettes used primarily in downstream and ultrafiltration processes. Its desktop portfolio includes MAVERICK and MAVEN, REBEL, and ZipChip.
Turnaround to Loss
The company's performance has turned to a loss, with the latest annual loss of USD .
Overvalued
The company’s latest PE is 5641.22, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 55.23M shares, decreasing 10.18% quarter-over-quarter.
Held by Scotia Canadian Dividend Fund
Star Investor Scotia Canadian Dividend Fund holds 40.66K shares of this stock.
Financial Health
Currency: USD Updated: 2025-12-12The current financial score of Repligen Corp is 9.11, ranking 12/208 in the Healthcare Equipment & Supplies industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 188.81M, representing a year-over-year increase of 21.91%, while its net profit experienced a year-over-year increase of 2379.97%.
Score
Financials
10.00
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
9.99
Operational Efficiency
9.56
Growth Potential
8.60
Shareholder Returns
7.41
Repligen Corp's Company Valuation
Currency: USD Updated: 2025-12-12The current valuation score of Repligen Corp is 7.45, ranking 88/208 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is 5641.22, which is 9.13% below the recent high of 6156.27 and 137.82% above the recent low of -2133.75.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 19/208
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2025-12-12The current earnings forecast score of Repligen Corp is 8.09, ranking 57/208 in the Healthcare Equipment & Supplies industry. The average price target for Repligen Corp is 190.00, with a high of 220.00 and a low of 160.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
22
analysts
Buy
Current Rating
187.959
Target Price
+16.88%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
112
Total
6
Median
9
Average
Company name
Ratings
Analysts
Repligen Corp
RGEN
22
Medtronic PLC
MDT
35
Stryker Corp
SYK
32
Abbott Laboratories
ABT
31
Dexcom Inc
DXCM
31
Zimmer Biomet Holdings Inc
ZBH
30
1
2
3
...
23
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2025-12-12The current price momentum score of Repligen Corp is 7.16, ranking 103/208 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 172.66 and the support level at 143.46, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
160.866
Sell
MA10
163.296
Sell
MA20
162.028
Sell
MA50
155.547
Buy
MA100
138.690
Buy
MA200
134.716
Buy
Institutional Confidence
Currency: USD Updated: 2025-12-12The current institutional shareholding score of Repligen Corp is 10.00, ranking 1/208 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 98.12%, representing a quarter-over-quarter decrease of 11.06%. The largest institutional shareholder is The Vanguard, holding a total of 5.03M shares, representing 8.94% of shares outstanding, with 0.91% decrease in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
BlackRock Institutional Trust Company, N.A.
Roy T. Eddleman UEO
Fidelity Management & Research Company LLC
State Street Investment Management (US)
Citadel Advisors LLC
Holocene Advisors, LP
1
2
Risk Assessment
Currency: USD Updated: 2025-12-12The current risk assessment score of Repligen Corp is 6.84, ranking 51/208 in the Healthcare Equipment & Supplies industry. The company's beta value is 1.12. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.
Score
Beta vs S&P 500 index
1.12
VaR
+4.92%
240-Day Maximum Drawdown
+37.51%
240-Day Volatility
+53.41%
Return
Best Daily Return
60 days
+9.08%
120 days
+9.08%
5 years
+17.86%
Worst Daily Return
60 days
-5.92%
120 days
-6.81%
5 years
-13.22%
Sharpe Ratio
60 days
+2.76
120 days
+1.46
5 years
+0.19
Risk Assessment
Maximum Drawdown
240 days
+37.51%
3 years
+47.75%
5 years
+66.41%
Return-to-Drawdown Ratio
240 days
+0.22
3 years
-0.11
5 years
-0.05
Skewness
240 days
+0.27
3 years
+0.49
5 years
+0.26
Volatility
Realised Volatility
240 days
+53.41%
5 years
+50.55%
Standardised True Range
240 days
+4.08%
5 years
+4.86%
Downside Risk-Adjusted Return
120 days
+270.93%
240 days
+270.93%
Maximum Daily Upside Volatility
60 days
+34.86%
Maximum Daily Downside Volatility
60 days
+25.34%
Liquidity
Average Turnover Rate
60 days
+1.43%
120 days
+1.48%
5 years
--
Turnover Deviation
20 days
+4.49%
60 days
+14.60%
120 days
+19.07%
Peer Comparison
Healthcare Equipment & Supplies
Repligen Corp
RGEN
8.13 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Lantheus Holdings Inc
LNTH
8.62 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
LivaNova PLC
LIVN
8.61 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Becton Dickinson and Co
BDX
8.46 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Tactile Systems Technology Inc
TCMD
8.43 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Align Technology Inc
ALGN
8.39 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
FAQs
How does TradingKey generate the Stock Score of Repligen Corp?
The TradingKey Stock Score provides a comprehensive assessment of Repligen Corp based on 34 indicators derived from over 100 underlying data points. These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Repligen Corp’s performance and outlook.
How do we generate the financial health score of Repligen Corp?
To generate the financial health score of Repligen Corp, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns. By integrating these comprehensive data, the financial health score not only reflects Repligen Corp's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Repligen Corp.
How do we generate the company valuation score of Repligen Corp?
To generate the company valuation score of Repligen Corp, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Repligen Corp’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value. By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Repligen Corp’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Repligen Corp.
How do we generate the earnings forecast score of Repligen Corp?
To calculate the earnings forecast score of Repligen Corp, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.Comparing these indicators against peers provides context for the stock’s performance and helps
anchor more realistic expectations.These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Repligen Corp’s future.
How do we generate the price momentum score of Repligen Corp?
When generating the price momentum score for Repligen Corp, we examine momentum indicators including support and resistance levels as well as volume metrics.Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.This comprehensive approach can reflect market sentiment and enable rational forecasts of Repligen Corp’s prices. A higher score indicates a more stable short-term price trend for Repligen Corp.
How do we generate the institutional confidence score of Repligen Corp?
To generate the institutional confidence score of Repligen Corp, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Repligen Corp’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Repligen Corp.
How do we generate the risk management score of Repligen Corp?
To assess the risk management score of Repligen Corp, we examine multiple key indicators related to returns, risk, volatility, and liquidity.The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.These indicators together provide a multi-dimensional understanding of Repligen Corp’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Repligen Corp.
